BIOCRYST PHARMACEUTICALS INC (BCRX)       12.8  +0.2 (+1.59%)

12.8  +0.2 (+1.59%)

US09058V1035 - Common Stock - After market: 12.81 +0.01 (+0.08%)

Buy % Consensus

74
Analysts have set a mean price target of 18.67. This target is 45.83% above the current price.
BCRX was analyzed by 18 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about BCRX.
In the previous month the buy percentage consensus was at a similar level.
BCRX was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target

Price Low Median Mean High 12.8014.1416.3218.6731.50 - 10.47% 27.50% 45.83% 146.09%

Up and Down Grades

Date Firm Action Rating
2022-08-08 Oppenheimer Downgrade Outperform -> Perform
2022-08-05 Oppenheimer Downgrade Outperform -> Perform
2022-08-05 Barclays Maintains Equal-Weight
2022-08-05 Evercore ISI Group Downgrade Outperform -> In-Line
2022-04-18 Barclays Downgrade Overweight -> Equal-Weight
2022-04-12 RBC Capital Maintains Sector Perform
2022-04-11 Oppenheimer Maintains Outperform
2022-04-11 B of A Securities Downgrade Buy -> Neutral
2021-12-10 Oppenheimer Initiate Outperform
2021-11-04 RBC Capital Maintains Sector Perform
2021-11-04 Barclays Maintains Overweight
2021-08-06 JMP Securities Maintains Market Outperform
2021-08-06 RBC Capital Maintains Sector Perform
2021-08-06 Barclays Maintains Overweight
2021-08-06 Jefferies Downgrade Buy -> Hold
2021-08-06 HC Wainwright & Co. Maintains Buy
2021-08-03 Cantor Fitzgerald Initiate Overweight
2021-03-24 HC Wainwright & Co. Maintains Buy

Analyst Ratings Stock Screener Links

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA